Navigation Links
Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
Date:4/14/2008

y with potential applications in the treatment of solid tumors, has completed preclinical development. Two additional BiTE antibodies, targeting CEA and MCSP, are in preclinical development.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmun
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Changes in Management Team
4. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
11. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... face of regulatory and marketplace changes. CI leaders who ... In a new Best Practices, LLC ... host of actionable insights, including: - Use ... cheaper than primary research - Internal staff ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 4, 2011 Photocure (OSE: PHO), a Norwegian specialty ... positive results from its consumer trial with Allumera™, a ... The RevitAll study was performed with ... treatment with Allumera™ improves skin appearance, when compared to ...
... 2011 MEDfx Corporation today announced a Direct Project ... a combination of the standards and protocols supported by ... is participating in, and is a contributor to, the ... Coordinator of Health IT.  The MEDfx Direct pilot will ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4MEDfx to Harmonize the Direct Project With CONNECT 2MEDfx to Harmonize the Direct Project With CONNECT 3
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. ... given to two American aid workers successfully cured a group ... researchers report. The drug, ZMapp, prompted recovery in all ... the medication until five days after infection. ZMapp even ... or even hours away from death, said study senior author ...
(Date:9/1/2014)... Monday 1 September 2014: Permanent atrial fibrillation (AF) doubles ... to research in more than 6 000 patients presented ... Belgium. The findings suggest that a simple clinical assessment ... better estimate stroke risk. , Ischaemic stroke is the ... over a million deaths and many more disabled patients ...
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Bioinformatics refers to an interdisciplinary ... and genetic data. A major part of this ... tools to generate and process useful biological data. ... computation. While bioinformatics simply makes use of computers ... related concepts, biological computation refers to the subfield ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( ... conference in September, where issues related to claims involving ... District of Pennsylvania, Bernstein Liebhard LLP reports. , ... the Court’s website, the meeting is scheduled to take ... is the latest of several Tylenol conferences that have ...
Breaking Medicine News(10 mins):Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4
... January 7, Discovery Health Presents Five Nights of Active, Viewing ... ... FIT TO LIVE -, SILVER SPRING, Md., Dec. 11 ... annual,weight loss and general wellness campaign-launches with a four-part,television event following ...
... American Red Cross Provides Tips on What to Do ... Dec. 11 American Red Cross,chapters throughout the Midwest ... outages and a frozen landscape, despite several,chapter offices being ... and employees are working from home or using partnerships ...
... Dec. 11 AIDS Healthcare,Foundation (AHF) today blasted ... Huckabee, for his stubbornness and,recent failure to apologize ... campaign in which he called for people living ... At the time, Huckabee,told Associated Press in response ...
... Consumers with Unaffordable Mandate, SANTA MONICA, Calif., Dec. ... as 14% have led a state panel,to propose a ... The vote,came less than a month before every citizen ... penalties that increase monthly, and as,California politicians and labor ...
... Party to Commit to Creating,Evidence Based National HIV/AIDS ... released a,statement today calling on Presidential Candidate Mike ... the policies he would undertake as,President conform to ... HIV. "Governor Huckabee,s 1992 statement calling for the,quarantine ...
... Nature, Brandeis University Howard Hughes Medical Investigator Dr. Dorothee ... secret lives of enzymes, the ubiquitous proteins that catalyze ... sophisticated technologies to capture a key enzyme changing shape ... that these proteins are not the wallflowers of the ...
Cached Medicine News:Health News:Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health 2Health News:Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health 3Health News:Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health 4Health News:Darkness and Cold Prevail in the Midwest 2Health News:Darkness and Cold Prevail in the Midwest 3Health News:Darkness and Cold Prevail in the Midwest 4Health News:Huckabee's Defense of Earlier, Alarmist AIDS Stance Shows Unsuitability for Presidency, Says AHF 2Health News:Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed 2Health News:AIDS Action Calls on Huckabee to Follow HIV/AIDS Science 2Health News:Caught in the act: The dynamic dance of enzymes 2
The Dolphin Medical 2150 Pulse Oximeter consists of the Dolphin ONE OEM 701 Module technology, (1) extension cable, and (1) oximetry sensor to non-invasively calculate the functional saturation of ar...
All-in-One Fingertip Oximeter...
... The Invacare Sleep Printing ... specifically designed to address ... a device that can ... conducting overnight screening for ...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: